ホーム › がん（全種類） › ミシガン州 › Detroit
Detroit、MIにおけるがん（全種類）の臨床試験
Detroitとその周辺地域（約30マイル以内）の拠点で、がん（全種類）に関する29件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
被験者募集中第3相
- Barbara Ann Karmanos Cancer Center, Detroit
- Henry Ford Cancer Institute-Henry Ford Hospital, Detroit
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
被験者募集中第3相
- Karmanos Cancer Center ( Site 0108), Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- Henry Ford Health Saint John Hospital, Detroit
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
被験者募集中第2/3相
- Karmanos Cancer Center Wayne State University, Detroit
Connect for Cancer Prevention Study (Connect)
被験者募集中観察研究健康なボランティア歓迎
- Henry Ford Health Systems, Detroit
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
被験者募集中第1/2相
- GSK Investigational Site, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
被験者募集中第1/2相
- Henry Ford Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
被験者募集中観察研究
- Karmanos Cancer Institute, Detroit
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Children's Hospital of Michigan, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Karmanos Cancer Institute, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Henry Ford Health Saint John Hospital, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
被験者募集中第1/2相
- Henry Ford Cancer Institute, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
被験者募集中第1相
- Henry Ford Hospital, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Henry Ford Hospital, Detroit
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
被験者募集中第2相
- Karmanos Cancer Center (Wayne State University), Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
被験者募集中第1相
- GSK Investigational Site, Detroit
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
被験者募集中第1相
- GSK Investigational Site, Detroit
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
被験者募集中第1/2相
- Karmanos Cancer Institute, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
被験者募集中第1相
- Henry Ford Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
被験者募集中第1/2相
- Henry Ford Health, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
被験者募集中第1相
- Karmanos Cancer Institute, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
被験者募集中
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
被験者募集中第1/2相
- Karmanos Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Henry Ford Cancer Institute, Detroit
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
被験者募集中第1/2相
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
被験者募集中観察研究
- Henry Ford Health System, Detroit
他の都市におけるがん（全種類）の試験
- Houston, TX121件の研究
- New York City, NY109件の研究
- Boston, MA85件の研究
- Los Angeles, CA74件の研究
- Nashville, TN65件の研究
- Philadelphia, PA59件の研究
- Washington, DC58件の研究
- Durham, NC58件の研究
- Chicago, IL51件の研究
- Atlanta, GA49件の研究
- Seattle, WA49件の研究
- Arlington, VA48件の研究
Detroitにおける他の研究
- 非小細胞肺癌44件の研究
- 乳がん33件の研究
- 大腸癌26件の研究
- 卵巣がん26件の研究
- 転移性癌24件の研究
- 前立腺がん22件の研究
- 子宮内膜がん21件の研究
- 肺がん20件の研究
- 多発性骨髄腫19件の研究
- 胃癌16件の研究
- 頭頸部扁平上皮癌15件の研究
- 急性骨髄性白血病14件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。